• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坦桑尼亚多多马地区慢性肝病患者中乙型和丙型肝炎病毒感染的血清流行率及预测因素:一项横断面研究

Seroprevalence and Predictors of Hepatitis B and C Virus Infections Among Patients with Chronic Liver Diseases in Dodoma Region, Tanzania: A Cross-Sectional Study.

作者信息

Gyunda Daudi J, Yahaya James J, Sindato Emmanuel M, Meremo Alfred J

机构信息

Department of Internal Medicine, School of Medicine and Dentistry, University of Dodoma, Dodoma, Tanzania.

Department of Pathology, School of Health Sciences, Soroti University, Soroti, Uganda.

出版信息

Hepat Med. 2025 Sep 23;17:125-140. doi: 10.2147/HMER.S533485. eCollection 2025.

DOI:10.2147/HMER.S533485
PMID:41019879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12476176/
Abstract

BACKGROUND

The known major causes of chronic liver diseases (CLDs) include, hepatitis B virus (HBV) and hepatitis C virus (HCV); however, there is scarcity of data regarding their seroprevalence in Tanzania. We aimed to evaluate the seroprevalence of HBsAg and anti-HCV and their predictors among patients with CLDs. Additionally, we also described the clinical patterns of the patients.

METHODS

A cross-sectional analytical study design was carried at the two referral public hospitals in Dodoma region; Dodoma referral regional hospital (DRRH) and Benjamin Mkapa hospital (BMH) among 118 patients with CLDs. Rapid test immunochromatography was used to test for HBsAg whereas anti-HCV antibody positivity was tested using lateral flow chromatographic immunoassay. Multivariable binary logistic regression was used to evaluate the predictors of HbsAg positive results, and statistical significance was set at p˂0.05.

RESULTS

The seroprevalence of HBsAg and anti-HCV antibody was 28% (33/118) and 3.4% (4/118), respectively. Having a chronic illness (AOR = 2.3, 95% CI = 1.76-7.19, p = 0.041), raised level of alanine transaminase (ALT) (AOR = 3.6, 95% CI = 1.74-8.21, p = 0.025), increased AST/ALT ratio (AOR = 2.9, 95% CI = 2.57-11.57, p = 0.039), and increased level of total bilirubin (AOR = 5.1, 95% CI = 1.09-24.39, p = 0.039) remained the predictors of HBsAg positivity.

CONCLUSION

This study reports that almost one-third of the study subjects had positive HbsAg, and the positivity of anti-HCV antibody was quite low. The positivity of HbsAg was associated with having chronic illness, increased levels of ALT, total bilirubin, and AST/ALT ratio. Therefore, emphasis should be made to maximize the screening practices for individuals with such predictors due to high possibility of being infected with HBV.

摘要

背景

慢性肝病(CLD)的已知主要病因包括乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV);然而,关于它们在坦桑尼亚的血清流行率的数据却很匮乏。我们旨在评估慢性肝病患者中HBsAg和抗-HCV的血清流行率及其预测因素。此外,我们还描述了患者的临床特征。

方法

在多多马地区的两家转诊公立医院——多多马转诊地区医院(DRRH)和本杰明·姆卡帕医院(BMH),对118例慢性肝病患者进行了一项横断面分析研究。采用快速检测免疫层析法检测HBsAg,而抗-HCV抗体阳性则采用侧向流动层析免疫测定法检测。使用多变量二元逻辑回归来评估HBsAg阳性结果的预测因素,统计学显著性设定为p˂0.05。

结果

HBsAg和抗-HCV抗体的血清流行率分别为28%(33/118)和3.4%(4/118)。患有慢性病(调整后比值比[AOR]=2.3,95%置信区间[CI]=1.76-7.19,p=0.041)、丙氨酸转氨酶(ALT)水平升高(AOR=3.6,95%CI=1.74-8.21,p=0.025)、天冬氨酸转氨酶/ALT比值升高(AOR=2.9,95%CI=2.57-11.57,p=0.039)以及总胆红素水平升高(AOR=5.1,95%CI=1.09-24.39,p=0.039)仍然是HBsAg阳性的预测因素。

结论

本研究报告称,几乎三分之一的研究对象HBsAg呈阳性,而抗-HCV抗体的阳性率相当低。HBsAg阳性与患有慢性病、ALT、总胆红素水平升高以及AST/ALT比值升高有关。因此,鉴于感染HBV的可能性很高,应重视对具有此类预测因素的个体加强筛查措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/e2a31efd426a/HMER-17-125-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/12ba1bcb93ed/HMER-17-125-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/3f8b2f400d1a/HMER-17-125-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/e2a31efd426a/HMER-17-125-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/12ba1bcb93ed/HMER-17-125-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/3f8b2f400d1a/HMER-17-125-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2333/12476176/e2a31efd426a/HMER-17-125-g0003.jpg

相似文献

1
Seroprevalence and Predictors of Hepatitis B and C Virus Infections Among Patients with Chronic Liver Diseases in Dodoma Region, Tanzania: A Cross-Sectional Study.坦桑尼亚多多马地区慢性肝病患者中乙型和丙型肝炎病毒感染的血清流行率及预测因素:一项横断面研究
Hepat Med. 2025 Sep 23;17:125-140. doi: 10.2147/HMER.S533485. eCollection 2025.
2
Investigation of Hepatitis C, D, and HIV Seroprevalence and Evaluation of APRI and FIB-4 Scores in HbsAg-Positive Patients.乙肝表面抗原阳性患者丙型肝炎、丁型肝炎和艾滋病毒血清流行率调查及APRI和FIB-4评分评估
Viruses. 2025 Apr 15;17(4):568. doi: 10.3390/v17040568.
3
Vesicoureteral Reflux膀胱输尿管反流
4
Seroprevalence of hepatitis B and hepatitis C viral infections among refugees in Muzaffarabad, Pakistan.巴基斯坦穆扎法拉巴德难民中乙型和丙型肝炎病毒感染的血清流行率。
BMC Infect Dis. 2025 Sep 29;25(1):1212. doi: 10.1186/s12879-025-11636-5.
5
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明:2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.
6
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
7
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
8
Risk of HBV reactivation in psoriasis vulgaris patients receiving biological agent therapy.接受生物制剂治疗的寻常型银屑病患者发生乙肝病毒再激活的风险。
Cutan Ocul Toxicol. 2025 Mar;44(1):113-117. doi: 10.1080/15569527.2025.2475444. Epub 2025 Mar 8.
9
Mid Forehead Brow Lift额中眉提升术
10
Prevalence and Risk Factors of Hepatocellular Carcinoma in Patients Co-infected With Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV): A Cross-Sectional Retrospective Study.乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)合并感染患者肝细胞癌的患病率及危险因素:一项横断面回顾性研究
Cureus. 2025 Jun 14;17(6):e85985. doi: 10.7759/cureus.85985. eCollection 2025 Jun.

本文引用的文献

1
Liver diseases: epidemiology, causes, trends and predictions.肝脏疾病:流行病学、病因、趋势及预测
Signal Transduct Target Ther. 2025 Feb 5;10(1):33. doi: 10.1038/s41392-024-02072-z.
2
Seroprevalence of hepatitis B and hepatitis C virus among clinically suspected cases of viral hepatitis visiting Guhalla Primary Hospital, Northwest Ethiopia.在埃塞俄比亚西北部的古哈拉初级医院就诊的疑似病毒性肝炎患者中乙型肝炎和丙型肝炎病毒的血清流行率。
Sci Rep. 2024 Sep 20;14(1):21956. doi: 10.1038/s41598-024-71363-w.
3
Sociodemographic and clinical features related to hepatitis B virus infection among rejected blood donors in Luanda, Angola.
安哥拉罗安达被拒献血者中与乙型肝炎病毒感染相关的社会人口学和临床特征。
Health Sci Rep. 2024 Aug 6;7(8):e2287. doi: 10.1002/hsr2.2287. eCollection 2024 Aug.
4
Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives.接受全身治疗的肝细胞癌患者门静脉高压症的管理:当前证据与未来展望
Cancers (Basel). 2024 Mar 31;16(7):1388. doi: 10.3390/cancers16071388.
5
Association of AST/ALT ratio with 90-day outcomes in patients with acute exacerbation of chronic liver disease: a prospective multicenter cohort study in China.慢性肝病急性加重患者谷草转氨酶/谷丙转氨酶比值与90天预后的关联:一项中国前瞻性多中心队列研究
Front Med (Lausanne). 2024 Mar 21;11:1307901. doi: 10.3389/fmed.2024.1307901. eCollection 2024.
6
Recognizing skin conditions in patients with cirrhosis: a narrative review.识别肝硬化患者的皮肤状况:一篇叙述性综述。
Ann Med. 2022 Dec;54(1):3017-3029. doi: 10.1080/07853890.2022.2138961.
7
Serum biomarkers for liver fibrosis.血清纤维化生物标志物。
Clin Chim Acta. 2022 Dec 1;537:16-25. doi: 10.1016/j.cca.2022.09.022. Epub 2022 Sep 27.
8
Hepatitis B virus infection and HBeAg positivity among pregnant women in South West Uganda.乌干达西南部孕妇中的乙型肝炎病毒感染及HBeAg阳性情况
Afr J Lab Med. 2022 Aug 18;11(1):1784. doi: 10.4102/ajlm.v11i1.1784. eCollection 2022.
9
Hepatitis B Virus prevalence and serological profiles in a hospital in Southern Italy.意大利南部一家医院的乙肝病毒流行情况及血清学特征
New Microbiol. 2022 May 10;45(4).
10
Alanine aminotransferase to aspartate aminotransferase ratio and hepatitis B virus on metabolic syndrome: a community-based study.丙氨酸氨基转移酶/天冬氨酸氨基转移酶比值与乙型肝炎病毒对代谢综合征的影响:一项基于社区的研究。
Front Endocrinol (Lausanne). 2022 Jul 29;13:922312. doi: 10.3389/fendo.2022.922312. eCollection 2022.